Return Of Anti-commercial Bribery Campaign In China Could Benefit Big Companies And Blacklist Others
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Last month, China's Ministry of Health released a notice urging local health authorities to crack down on kickbacks to doctors in return for sales of pharmaceutical products under a policy that would ban drug manufacturers from participating in drug tenders in public hospitals for two years if they are blacklisted